GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Trius Therapeutics, Inc. (TSRX) [hlAlert]

Rating:
Buy TSRX
up 172.60 %

Trius Therapeutics, Inc. (TSRX) rated Buy with price target $18 by Aegis Capital

Posted on: Monday,  Mar 25, 2013  11:25 AM ET by Aegis Capital

Aegis Capital rated Buy Trius Therapeutics, Inc. (NASDAQ: TSRX) on 03/25/2013. Previously Aegis Capital rated Buy Trius Therapeutics, Inc. (NASDAQ: TSRX) on
11/19/2012., when the stock price was $5.00. Since then, Trius Therapeutics, Inc. has gained 172.60% as of 09/11/2014's recent price of $13.63.
If you would have followed the previous Aegis Capital's recommendation on TSRX, you would have gained 172.6% of your investment in 661 days.

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for life threatening infections. The Company is developing torezolid phosphate, an intraveneous (IV) and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections (ABSSSI), and subsequently for other indications. The Company initiated its Phase III clinical program for torezolid phosphate for the treatment of ABSSSI in August 2010. In addition, the Company is developing antibiotics for gram-negative infections using its discovery platform under two contracts: one funded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) and the other funded by the Defense Threat Reduction Agency (DTRA), a part of the Department of Defense.

Aegis Capital
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/25/2013 11:25 AM Buy
None
6.84 18.00
as of 12/13/2013
1 Week   
1 Month   
3 Months   
1 YTD up  185.14 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/24/2013 12:25 PM Buy
None
4.93 14.00
11/19/2012 9:25 AM Buy
None
5.00 15.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy